Digitala Vetenskapliga Arkivet

Planned maintenance
A system upgrade is planned for 17/11-2026, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Novel Synthetic Strategies for the Development of Peptides and Peptidomimetics in Alzheimer's Disease and Prostate Cancer
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry. (Preparativ Läkemedelskemi)ORCID iD: 0009-0008-6737-0336
2025 (English)Doctoral thesis, comprehensive summary (Other academic)
Description
Abstract [en]

Peptides are attractive therapeutic agents due to their high target affinity and specificity. However, their clinical application is often limited by poor metabolic stability, rapid renal clearance and low bioavailability, necessitating chemical modifications to generate viable drug candidates. This thesis addresses these challenges through the development of safer synthetic methods and the design of modified peptides targeting two clinically relevant proteins: the insulin-regulated aminopeptidase (IRAP) in Alzheimer’s disease and the gastrin-releasing peptide receptor (GRPR) in prostate cancer. The first part focuses on method development for the safer generation of diazomethane, a key reagent in peptide modification, particularly for the synthesis of β3-amino acids via α-diazoketones in the Arndt-Eistert homologation. However, diazomethane is explosive and carcinogenic, limiting its practical use. In Paper I, we report a method for the in situ generation of diazomethane through a click and release reaction between an enamine and a sulfonyl azide, thereby eliminating the hazardous handling of diazomethane. This strategy enabled the synthesis of α-diazoketones and methyl esters of carboxylic acids under mild, base-free conditions. The second part investigates structure–activity relationships (SAR) of modified peptides targeting IRAP and GRPR. In Paper II, twelve novel analogues of the macrocyclic IRAP inhibitor HA08 were synthesised via a new divergent route focusing on C-terminal modifications. IRAP inhibition has shown cognitive benefits in preclinical models of Alzheimer’s disease. Thus, inhibitors like HA08 are potential cognitive enhancers. However, this peptidomimetic suffers from poor metabolic stability, necessitating further structural modifications. The SAR study revealed that aromaticity and correct spatial orientation at the C-terminus were crucial for IRAP inhibition. Papers III and IV focus on the development of GRPR antagonists for imaging and therapy in early-stage prostate cancer. GRPR is overexpressed in prostate tumour cells but minimally expressed in healthy tissues, making it a valuable molecular target for theranostic application. In Paper III, the influence of rigidity and lipophilicity of aromatic linkers in 68Ga-labelled radiopeptides for PET imaging was explored. Moderate lipophilicity improved tumour uptake and imaging contrast, suggesting that fine-tuning linker properties can optimise radioligand pharmacokinetics. Finally, therapeutic application of GRPR antagonists requires enhancement of circulatory half-life to prolong tumour irradiation. In paper IV, albumin-binding moieties (ABMs) were incorporated into 117Lu-labelled radiopeptides, which extended circulatory half-life for all conjugates and increased GRPR-mediated uptake. The position and lipophilicity of the ABM strongly influenced biodistribution profile of the radioconjugates, with [177Lu]Lu-CA6356 and [177Lu]Lu-CA6357 showing the most favourable profile. 

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2025. , p. 117
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 380
Keywords [en]
Peptides, peptidomimetics, insulin-regulated aminopeptidase (IRAP), inhibitor, neurodegenerative diseases, prostate cancer, gastrin-releasing peptide receptor (GRPR), radiopharmaceuticals, theranostics, PET imaging, Alzheimer’s Disease.
National Category
Medicinal Chemistry
Identifiers
URN: urn:nbn:se:uu:diva-564154ISBN: 978-91-513-2533-0 (print)OAI: oai:DiVA.org:uu-564154DiVA, id: diva2:1985765
Public defence
2025-09-12, B42, BMC, Husargatan 3, Uppsala, 13:15 (English)
Opponent
Supervisors
Available from: 2025-08-21 Created: 2025-07-28 Last updated: 2025-08-21
List of papers
1. A Base-Free, Low Temperature Click and Release Reaction for the In Situ Generation of Diazomethane
Open this publication in new window or tab >>A Base-Free, Low Temperature Click and Release Reaction for the In Situ Generation of Diazomethane
Show others...
2023 (English)In: Advanced Synthesis and Catalysis, ISSN 1615-4150, E-ISSN 1615-4169, Vol. 365, no 11, p. 1839-1845Article in journal (Refereed) Published
Abstract [en]

Diazomethane is a powerful reagent for numerous chemical reactions such as esterifications and the homologation of carboxylic acids. Unfortunately, the synthetic utility of diazomethane is severely limited by its toxicity and highly explosive nature. Diazald((R)) is typically used for ex situ synthesis, however it requires cumbersome and hazardous transfer of diazomethane from a caustic aqueous phase to the reaction medium. Herein, we present a low temperature and base-free insitu synthesis of diazomethane via a "click and release" reaction between an enamine and sulfonyl azide. Its utility is exemplified by the synthesis of diverse methyl esters in yields of up to 93%. Moreover, diazoketone synthesis from insitu generated diazomethane and acid chlorides was demonstrated for the first time. Finally, trideuteromethylation was achieved using acetone-d(6) as the deuterium source. We anticipate that this method will enable the safer use of diazomethane in organic synthesis and drug discovery programs.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2023
Keywords
diazomethane, diazo compounds, C1 building blocks, click chemistry, chemoselectivity
National Category
Organic Chemistry
Identifiers
urn:nbn:se:uu:diva-511113 (URN)10.1002/adsc.202300132 (DOI)000993764200001 ()
Funder
Swedish Research Council, Vetenskapsradet 2018-05133Swedish Research Council, 2022-04831Swedish Research Council
Available from: 2023-09-13 Created: 2023-09-13 Last updated: 2025-07-28Bibliographically approved
2. Novel Macrocyclic Peptidomimetics Targeting the Insulin-Regulated Aminopeptidase (IRAP): Design, Synthesis and Evaluation
Open this publication in new window or tab >>Novel Macrocyclic Peptidomimetics Targeting the Insulin-Regulated Aminopeptidase (IRAP): Design, Synthesis and Evaluation
Show others...
2025 (English)In: RSC Medicinal chemistry, ISSN 2632-8682, Vol. 16, no 10, p. 5059-5069Article in journal (Refereed) Published
Abstract [en]

Inhibition of the Insulin-Regulated Aminopeptidase (IRAP) is a promising therapeutic strategy for neurodegenerative disorders such as Alzheimer's disease, due to its role in cognitive processes. HA08, a macrocyclic peptidomimetic derived from Angiotensin IV, is among the most potent known IRAP inhibitors (IC50 = 18 nM). However, detailed structure-activity relationship (SAR) studies at its C-terminus have been limited by synthetic constraints. Herein, we report the design, synthesis, and biological evaluation of a focused series of HA08 analogues to explore the impact of C-terminal modifications on IRAP inhibition. An improved convergent synthetic route was established via a common macrocyclic intermediate, enabling late-stage diversification through coupling with non-natural amino acids which led to the synthesis of twelve novel peptidomimetic scaffolds. Several analogues retained high potency, with one-carbon elongation next to the carboxylic acid moiety or secondary amine being well tolerated. In contrast, aliphatic analogues exhibited markedly reduced potency, highlighting the importance of π-π interactions, while the low activity of phenoxyacetic acid derivatives likely reflects altered geometry within the binding pocket. The most potent inhibitor in the series featured a C-terminal benzyl alcohol (IC50 = 59 nM), approaching the activity of HA08. To rationalize these SAR trends, molecular dynamics simulations were performed based on the IRAP-HA08 co-crystal structure. Partial Least Squares analysis of protein-ligand contact patterns revealed that sustained interactions between the C-terminal carboxylate and Arg929 correlated with lower potency, whereas interaction with Arg439 was associated with enhanced activity. These findings suggest that subtle shifts in C-terminal positioning influence binding mode and potency, providing vable imsight the findings of the SAR study on C-terminal modifications provide valuable insights for the design of future IRAP inhibitors.

Place, publisher, year, edition, pages
Royal Society of Chemistry, 2025
National Category
Medicinal Chemistry
Identifiers
urn:nbn:se:uu:diva-564133 (URN)10.1039/d5md00438a (DOI)001556312800001 ()40881305 (PubMedID)
Funder
The Swedish Brain Foundation, FO2024-0317-HK-70Swedish Cancer Society, 24 3889 PjKjell and Marta Beijer FoundationScience for Life Laboratory, SciLifeLabUppsala University
Available from: 2025-07-25 Created: 2025-07-25 Last updated: 2026-01-08Bibliographically approved
3. A preclinical study on the influence of linkers in [68Ga]Ga-NOTA-X-RM26 radiotracers for PET imaging of GRPR expression
Open this publication in new window or tab >>A preclinical study on the influence of linkers in [68Ga]Ga-NOTA-X-RM26 radiotracers for PET imaging of GRPR expression
Show others...
2025 (English)In: EJNMMI Research, E-ISSN 2191-219X, Vol. 15, no 1, article id 104Article in journal (Refereed) Published
Abstract [en]

Background

Gastrin-releasing peptide receptor (GRPR) is overexpressed in several cancers, including prostate and breast, making it an attractive target for radiopharmaceutical development. Studies on GRPR-targeting radioligands highlight the critical role of the spacer region between the GRPR-recognition motif and radiolabeled moiety, which can significantly influence peptide pharmacokinetics and pharmacodynamics. Herein, we investigated the impact of structurally restricted spacers on the performance of RM26-based radioligands.

Results

Three novel radioligands were designed to each bear a NOTA chelator via different spacers composed of N-acetyl-lysine followed by either o-ethyltoluene (oET), o-methylanisole (oMA), or m-methylanisole (mMA) motifs. The peptides were successfully labeled with Ga-68, achieving high radiochemical yield, purity, and molar activity. The resulting [68Ga]-labeled peptides demonstrated high and GRPR-specific binding to prostate cancer PC-3 cells, antagonistic behavior, and the IC50 values to GRPR were in the single-digit nanomolar range. Biodistribution studies at 2 h post-injection in PC-3 xenograft-bearing mice revealed high, GRPR-mediated tumor uptake for all three radioligands. In addition, high hepatobiliary excretion with elevated uptake in the liver and the gastrointestinal tract and pronounced pancreatic uptake were observed.

Conclusions

Among the three radioligands, the peptide bearing the N-acetyl-lysine-oET spacer exhibited the fastest background clearance and better PET imaging of prostate cancer xenografts. The incorporation of conformationally restricted spacers is a promising strategy for developing tracers with high GRPR binding and good imaging properties, but further optimization is necessary to reduce uptake in healthy tissues.

Place, publisher, year, edition, pages
Springer, 2025
Keywords
Radiopharmaceuticals, GRPR, Bombesin analogue, Antagonist, Prostate cancer, Structure-properties relationship
National Category
Medicinal Chemistry Radiology and Medical Imaging Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-564152 (URN)10.1186/s13550-025-01301-y (DOI)001545786000002 ()40775579 (PubMedID)2-s2.0-105012737092 (Scopus ID)
Note

De två första författarna delar förstaförfattarskapet

De två sista författarna delar sistaförfattarskapet

Authors in the list of papers of Esther Olaniran Håkansson's thesis: Olaniran Håkansson, E., Zelepukin, I.V., Obeid, K., Bitzios, A., Bezverkhniaia, E., Sunkara, A., Orlova, A., Odell, L.R., Kanellopoulos, P.

Available from: 2025-07-27 Created: 2025-07-27 Last updated: 2025-09-03Bibliographically approved
4. Tuning the Pharmacokinetics of GRPR Radioligands via Albumin-Binding Moieties for Therapeutic Application in Prostate Cancer
Open this publication in new window or tab >>Tuning the Pharmacokinetics of GRPR Radioligands via Albumin-Binding Moieties for Therapeutic Application in Prostate Cancer
Show others...
(English)Manuscript (preprint) (Other academic)
National Category
Medicinal Chemistry
Identifiers
urn:nbn:se:uu:diva-564153 (URN)
Available from: 2025-07-27 Created: 2025-07-27 Last updated: 2025-07-28

Open Access in DiVA

UUThesis_Olaniran Håkansson,E-2025(3972 kB)544 downloads
File information
File name FULLTEXT01.pdfFile size 3972 kBChecksum SHA-512
ff2c3a968dffa35ccae8beb511f5d062c371026782643960d113dd9088ce3a775af68aa2b0eeb9e3e584cb4beb2c735b541b725ddec2dd66b343fd1d034012aa
Type fulltextMimetype application/pdf

Search in DiVA

By author/editor
Olaniran Håkansson, Esther
By organisation
Department of Medicinal Chemistry
Medicinal Chemistry

Search outside of DiVA

GoogleGoogle Scholar
Total: 548 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

isbn
urn-nbn

Altmetric score

isbn
urn-nbn
Total: 1941 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf